Pharma, Pharmaceutics and Biotechnology Conference

Drug resistance, particularly antimicrobial resistance, threatens global health in increasing morbidity and mortality and pumping up healthcare cost.

The session will discuss drug resistance in different therapeutic areas, particularly its mechanisms, impact on treatment outcome, and the urgent need for novel solutions. Understanding Drug Resistance: It is basically the ability of the pathogen to resist the action of the medication.

The development has been majorly culminated by overt prescription of antibiotics, incomplete treatment courses, and antibiotic use in animals. It is important to understand the mechanisms involved to develop the right action to contain resistance.

This rise in resistance compounds the management of treatment, hospital stays, more expensive medications, and mortality. In this session, we will bring attention to some of the key statistics and case studies about the rising tide of drug resistance and its burden on healthcare systems around the world.

Some of the public health initiatives to monitor and combat antibiotic resistance will be deliberated by experts through the use of antibiotic stewardship programs. New Antibiotic Resistance Therapies: Novel therapies and alternatives to the conventional use of antibiotics are being developed in the pharma industry.

We are going to discuss pioneering research in bacteriophage therapy, antimicrobial peptides, and vaccines that prevent infections during panel discussions featuring senior researchers and industry people working on pioneering solutions for the drug resistance dilemma.

Participants leave this session with a new appreciation of the complexity of drug resistance and the collaborative solutions needed to combat this important public health issue globally.